Parathyroidectomy,
does it really help with Prevention of death and major disease in mild primary hyperparathyroidism?
research showsThe grade is D. In the 191-participant randomized SIPH trial across eight Scandinavian centers, 10-year deaths numbered 8 with surgery and 7 with observation, while prespecified major morbidity events numbered 52 versus 49. Seventeen observation participants (17.7%) crossed to surgery within 10 years, and only 129 completed the 10-year visit, so the null result cannot establish complete equivalence.
ads claimBiochemical normalization of PTH and calcium cannot be extended automatically to longer survival or fewer major diseases in mild cases. This trial did not show event benefit, but crossover and attrition also prevent a claim that every meaningful benefit was excluded.
Useful facts when choosing a product
- Participants were adults aged 50–80 with mild rather than severe complicated primary hyperparathyroidism.
- Seventeen observation participants, 17.7%, underwent surgery within 10 years.
- Only 129 of 191 completed the 10-year visit.
What the research actually shows
SIPH randomized 191 untreated adults aged 50–80 with mild primary hyperparathyroidism to parathyroidectomy (95) or observation (96). Ten-year deaths were 8 versus 7; 101 prespecified major morbidity events were 52 versus 49; vertebral fractures occurred in 7 participants per group. Extended mortality through 2018 was 24 versus 20. Sixty-two participants (32%) did not complete the 10-year visit, while formal withdrawals were 23 surgical and 27 observation participants, 50 (26%) in total. The 15 deaths at 10 years were primary-endpoint events, not attrition. Seventeen observation participants (17.7%) crossed to surgery, which could dilute group separation. Funding came from the Swedish government, Norwegian Research Council, and South-Eastern Norway Regional Health Authority.
Why this is classified as D (34)
Publicly funded hard-outcome evidence is a strength, but one 191-participant null trial with 50 formal withdrawals (26%) gives D with 34 points. Observation-to-surgery crossover could dilute group separation.
Counterpoint. The null result concerns mortality and major-disease prevention, not biochemical cure. Bone density or symptoms require separate evidence.
Rejudgment record. Cross-check applied — Centers the null 10-year mortality and morbidity outcomes while accounting for the small sample of 191 and 50 formal withdrawals (26%); 17.7% crossover is a dilution factor
| Endpoint | H | Hard endpoint - actual events such as death |
| Replication | R1 | Single confirmatory trial |
| Independence | I2 | Decisive evidence is publicly or non-profit funded |
| Effect size | E0 | Null |
| Precision | C0 | The confidence interval leaves room for benefit |
The scoring table and the verdict agree (D).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Reduced 10-year mortality | D | Deaths were 8 versus 7, with no reduction. |
| Prevention of major morbidity | D | Prespecified events numbered 52 versus 49. |
| Biochemical normalization | A | This direct surgical effect is separate from the long-term event verdict. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Study 1 | Prospective randomized surgery-versus-observation trial at eight Scandinavian centers | 26 | Swedish government, Norwegian Research Council, and South-Eastern Norway Regional Health Authority | All-cause mortality at 10 years and prespecified major morbidity events | Deaths 8 versus 7, extended through 2018 to 24 versus 20; major morbidity events 52 versus 49; vertebral fractures 7 per group; 17 observation participants (17.7%) crossed to surgery | Single publicly funded hard-outcome trial; small sample of 191 and 50 formal withdrawals (26%); crossover as a dilution factor |
Receipt — 1 References
All 1 cited sources were verified for existence at the original page (as of 2026-08-18).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-08-18 · Corrections: none
Cite this verdict
[Chamgap] Parathyroidectomy x death and major disease in mild primary hyperparathyroidism — Evidence Grade D·34. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/joint-bone/parathyroidectomy-mild-primary-hyperparathyroidism-mortality-morbidity/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.